Long-term oral carvedilol in chronic heart failure

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1359-1372

  Di Lenarda, Andrea ^a   Sabbadini, Gastone ^b   Moretti, Michele ^a   Sinagra, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

blocker therapy; Carvedilol; Chronic heart failure; Sympathetic nervous system

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENOXIMONE; FLUOXETINE; HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; RIFAMPICIN; WARFARIN;

ASTHENIA; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FATIGUE; FOOD DRUG INTERACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; KIDNEY DISEASE; LIVER DISEASE; LIVER METABOLISM; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; REVIEW; SYNCOPE;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHRONIC DISEASE; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HUMANS; PRACTICE GUIDELINES; PROPANOLAMINES; TIME FACTORS;

EID: 3142528609     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1359     Document Type: Review

References (108)

1. COWIE MR, MOSTERD A, WOOD DA et al.: The epidemiology of heart failure. Eur. Heart J. (1997) 18(2):208-225.
2. PACKER M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. (1992) 20(1):248-254.
3. FRANCIS GS, GOLDSMITH SR, LEVINE TD, OLIVARI MT, COHN JN: The neurohormonal axis in congestive heart failure. Ann. Intern. Med. (1984) 101 (3):370-377.
4. COLUCCI WS: Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. (1997) 80(11A):15L-25L.
5. COHN JN: Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation (1995) 91(10):2504-2507.
6. PODRID PJ, FUCHS T, CANDINAS R: Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation (1990) 82(Suppl. I):I103-I113.
7. BRISTOW MR: Mechanism of action of beta-blocking agents in heart failure. Am. J. Cardiol. (1997) 80(11A):26L-40L.
8. MORGAN T: Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. (1994) 26(5):335-346.
9. VON MOLLENDORFF E, REIFF K, NEUGEBAUER G: Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur. J. Clin. Pharmacol. (1987) 33(5):511-513.
10. NEUGEBAUER G, AKPAN W, KAUFMANN B, REIFF K: Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur. J. Clin. Pharmacol. (1990) 38(2):108-111.
11. CARLSON W, OBERG K: Clinical pharmacology of carvedilol. J. Cardiovasc. Pharmacol. Ther. (1999) 4(4):205-218.
12. OLDHAM HG, CLARKE SE: In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. (1997) 25(8):970-977.
13. NEUGEBAUER G, AKPAN W, VON MOLLENDORFF E, NEUBERT P, REIFF K: Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. (1987) 10(Suppl. 11):S85-S88.
14. FEUERSTEIN GZ, RUFFOLO RR Jr: Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J. (1995) 16(Suppl. 11):38-42.
15. FRISHMAN WH: Carvedilol. N. Engl. J. Med. (1998) 339(24):1759-1765.
16. MORGAN T, ANDERSON A, CRIPPS J, ADAM W: Pharmacokinetics of carvedilol in older and younger patients. J. Hum. Hypertens. (1990) 4(6):709-715.
17. ZHOU HH, WOOD AJ: Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther. (1995) 57(5):518-524.
18. TENERO D, ILSON B, BOYLE D et al.: Dose-proportional stereoselective kinetics of carvedilol in patients with CHF. Clin. Pharmacol. Ther. (1996) 59(2):201.
19. GEHR TW, TENERO DM, BOYLE DA, QIAN Y, SICA DA, SHUSTERMAN NH: The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur. J. Clin. Pharmacol. (1999) 55(4):269-277.
20. CICE G, FERRARA L, DI BENEDETTO A et al.: Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. (2001) 37(2):407-411.
21. NEUGEBAUER G, GABOR M, REIFF K: Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs (1988) 36(Suppl. 6):148-151.
22. LOUIS WJ, MCNEIL JJ, WORKMAN BS, DRUMMER OH, CONWAY EL: A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J. Cardiovasc. Pharmacol. (1987) 10(Suppl. 11): S89-S93.
23. GRAFF DW, WILLIAMSON KM, PIEPER JA et al.: Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J. Clin. Pharmacol. (2001) 41(1):97-106.
24. DE MEY C, BRENDEL E, ENTERLING D: Carvedilol increases the systemic bioavailability of oral digoxin. Br. J. Clin. Pharmacol. (1990) 29(4):486-490.
25. KAIJSER M, JOHNSSON C, ZEZINA L, BACKMAN U, DIMENY E, FELLSTROM B: Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin. Transplant. (1997) 11(6):577-581.
26. GIESSMANN T, MODESS C, HECKER U et al.: CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin. Pharmacol. Ther. (2004) 75(3):213-222.
27. METRA M, NODARI S, DEI CAS L: Beta-blockade in heart failure: selective versus nonselective agents. Am. J. Cardiovasc. Drugs (2001) 1(1):3-14.
28. KAYE DM, SMIRK B, WILLIAMS C, JENNINGS G, ESLER M, HOIST D: Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 13(7):379-382.
29. KUBO T, AZEVEDO ER, NEWTON GE, PARKER JD, FLORAS JS: Lack of evidence for peripheral alpha(1)-adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J. Am. Coll. Cardiol. (2001) 38(5):1463-1469.
30. KRUM H, SACKNER-BERNSTEIN JD, GOLDSMITH RL et al.: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation (1995) 92(6):1499-1506.
31. OLSEN SL, GILBERT EM, RENLUND DG, TAYLOR DO, YANOWITZ FD, BRISTOW MR: Carvedilol improves left ventricular function and symptoms in chronic heart figure: a double-blind randomized study. J. Am. Coll. Cardiol. (1995) 25(6):1225-1231.
32. BRISTOW MR, GILBERT EM, ABRAHAM WT et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation (1996) 94(11):2807-2816.
33. COHN JN, FOWLER MB, BRISTOW MR et al.: Safety and efficacy of carvedilol in severe heart failure. The US Carvedilol Heart Failure Study Group. J. Card. Fail. (1997) 3(3):173-179.
34. AUSTRALIA/NEW ZEALAND Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet (1997) 349(9049):375-380.
35. GUAZZI M, AGOSTONI P, MATTURRI M, PONTONE G, GUAZZI MD: Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am. Heart J. (1999) 138(3 Pt 1):460-467.
36. DOUGHTY RN, WHALLEY GA, GAMBLE G, MACMAHON S, SHARPE N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J. Am. Coll. Cardiol. (1997) 29(5):1060-1066.
37. PALAZZUOLI A, BRUNI F, PUCCETTI L et al.: Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur. J. Heart Fail. (2002) 4(6):765-770.
38. COLUCCI WS, PACKER M, BRISTOW MR et al.: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 94(11):2800-2806.
39. PACKER M, COLUCCI WS, SACKNER-BERNSTEIN JD et al.: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation (1996) 94(11):2793-2799.
40. PACKER M, ANTONOPOULOS GV, BERLIN JA, CHITTAMS J, KONSTAM MA, UDELSON JE: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am. Heart J. (2001) 141 (6):899-907.
41. BERGSTROM A, ANDERSSON B, EDNER M et al.: Carvedilol improves diastolic function in patients with diastolic heart failure. Circulation (2001) 104(17 Suppl. 2):718.
42. SANDERSON JE, CHAN SK, YIP G et al.: Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J. Am. Coll. Cardiol. (1999) 34(5):1522-1528.
43. KUKIN ML, KALMAN J, CHARNEY RH et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation (1999) 99(20):2645-2651.
44. DI LENARDA A, SABBADINI G, SALVATORE L et al.: Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J. Am. Coll. Cardiol. (1999) 33(7):1926-1934.
45. METRA M, GIUBBINI R, NODARI S, BOLDI E, MODENA MG, DEI CAS L: Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (2000) 102(5):546-551.
46. DOUGHTY RN, WHALLEY GA, WALSH H, GAMBLE G, SHARPE N: Effects of carvedilol on left ventricular remodelling in patients following acute myocardial infarction: the CAPRICORN echo substudy. Circulation (2004) 109(2):201-206.
47. SENIOR R, BASU S, KINSEY C, SCHAEFFER S, LAHIRI A: Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am. Heart J. (1999) 137(4 Pt 1):646-652.
48. KHATTAR RS, SENIOR R, SOMAN P et al.: Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am. Heart J. (2001) 142(4):704-713.
49. REMME WJ, RIEGGER G, HILDEBRANDT P et al.: Do patients necessarily have to start with an angiotensin convening enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE inhibitor remodelling mild CHF Evaluation) study. J. Am. Coll. Cardiol. (2003) 41(6 Suppl. A): 162A.
50. REMME WJ, SOLER-SOLER J, RYDEN L et al.: Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodeling in mild heart failure and is well tolerated: results of the CARMEN (Carvedilol ACE-inhibitor Remodeling in Mild Heart Failure Evaluation) study. J. Am. Coll. Cardiol. (2003) 41(6 Suppl. A):205A.
51. DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357(9266):1385-1390.
52. BASU S, SENIOR R, RAVAL U, VAN DER DOES R, BRUCKNER T, LAHIRI A: Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation (1997) 96(1):183-191.
53. YUE TL, CHENG HY, LYSKO PG et al.: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. (1992) 263(1):92-98.
54. LYSKO PG, WEBB CL, GU JL, OHILSTEIN EH, RUFFOLO RR Jr, YUE TL: A comparison of carvedilol and metoprolol antioxidant activities in vitro. J. Cardiovasc. Pharmacol. (2000) 36(2):277-281.
55. NOGUCHI N, NISHINO K, NIKI E: Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol. (2000) 59(9):1069-1076.
56. OETTL K, GREILBERGER J, ZANGGER K, HASLINGER E, REIBNEGGER G, JURGENS G: Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem. Pharmacol. (2001) 62(2):241-248.
57. NAKAMURA K, KUSANO K, NAKAMURA Y et al.: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation (2002) 105(24):2867-2871.
58. ARUMANAYAGAM M, CHAN S, TONG S et al.: Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomised controlled trial. J. Cardiovasc. Pharmacol. (2001) 37(1):48-54.
59. ROMEO F, LI D, SHI M, MEHTA JL: Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc. Res. (2000) 45(3):788-794.
60. YUE TL, MA XL, WANG X et al.: Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ. Res. (1998) 82(2):166-174.
61. SUNG CR ARLETH AJ, OHLSTEIN EH: Carvedilol inhibits vascular smooth muscle cell proliferation. J. Cardiovasc. Pharmacol. (1993) 21(2):221-227.
62. PATEL MK, CHAN P, BETTERIDGE LJ, SCHACHTER M, SEVER PS: Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J. Cardiovasc. Pharmacol. (1995) 25(4):652-657.
63. ABRAHAM WT. TSVETKOVA T: LOWES BD et al.: Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation (1998) 98(Suppl. 1):378-379.
64. REFSGAARD J, ANDREASEN F, GOETZSCHE O et al.: Improvement of endothelial dysfunction in patients with congestive heart failure during treatment with carvedilol. Eur. Heart J. (1999) 20(Suppl.):375.
65. DE BOER RA, SIEBELINK HJ, TIO RA, BOOMSMA F, VAN VELDHUISEN DJ: Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. Eur. J. Heart Fail. (2001) 3(3):331-333.
66. OHLSTEIN EH, ARLETH AJ, STORER B, ROMANIC AM: Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J. Mol. Cell. Cardiol. (1998) 30(1):167-173.
67. OHTSUKA T, HAMADA M, SAEKI H et al.: Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy Am. J. Cardiol. (2002) 89(8):996-999.
68. REFSGAARD J, THOMSEN C, ANDREASEN F, GOTZSCHE O: Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eur. J. Heart Fail. (2002) 4(4):445-453.
69. BOTTCHER M, REFSGAARD J, GOTZSCHE O, ANDREASEN F, NIELSEN TT: Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am. J. Cardiol. (2002) 89(12):1388-1393.
70. METRA M, NARDI M, GIUBBINI R, DEI CAS L: Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. (1994) 24(7):1678-1687.
71. CLELAND JG, PENNELL DJ, RAY SG et al.: Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet (2003) 362(9377):14-21.
72. MACFARLANE PW, MURRAY GD, MCGOWAN J et al.: Analysis of 24 hour ambulatory ECGs from the CHRISTMAS study. Circulation (2002) 106(19 Suppl.):613.
73. CICE G, TAGLIAMONTE E, FERRARA L, IACONO A: Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur. Heart J. (2000) 21(15):1259-1264.
74. GILBERT EM, ABRAHAM WT, OLSEN S et al: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation (1996) 94(11):2817-2825.
75. MAACK C, ELTER T, NICKENIG G et al.: Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J. Am. Coll. Cardiol. (2001) 38(4):939-946.
76. PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. (1996) 334(21):1349-1355.
77. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344(22):1651-1658.
78. POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362(9377):7-13.
79. PACKER M, FOWLER MB, ROECKER EB et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 106(17):2194-2199.
80. KRUM H, ROECKER EB, MOHACSI P et al.: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 289(6):712-718.
81. MASSIE BM: A comment on COMET: how to interpret a positive trial? J. Card. Fail. (2003) 9:425-428.
82. SHEPHERD AMM: A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial. J. Card. Fail. (2003) 9:454-457.
83. PACKER M: Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J. Card. Fail. (2003) 9(6):429-443.
84. BRISTOW MR, FELDMAN AM, ADAMS KF JR, GOLDSTEIN S: Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J. Card. Fail. (2003) 9(6):444-453.
85. DARGIE HJ: Beta blockers in heart failure. Lancet (2003) 362(9377):2-3.
86. BRISTOW MR, GINSBURG R, UMANS V et al: β1- and β2-actrenergic receptor subpopulations in non failing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ. Res. (1986) 59:297-309.
87. JOHANSSON M, RUNDQVIST B, EISENHOFER G, FRIBERG P: Cardiorenal epinephrine kinetics: evidence for neuronal release in the human heart. Am. J. Physiol. (1997) 273(5 Pt 2):H2178-H2185.
88. HOULE MS, ALTSHULD RA, BILLMAN GE: Enhanced in vivo and in vitro contractile responses to β2-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias. J. Appl. Physiol. (2001) 91:1627-1637.
89. HALL JA, KAUMANN AJ, BROWN MJ: Selective β1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through β2-adrenoceptors in human atrial myocardium. Circ. Res. (1990) 66:1610-1623.
90. ASANO K, ZISMAN LS, YOSHIKAWA T et al.: Bucindolol, a nonselective beta 1-and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J. Cardiovasc. Pharmacol. (2001) 37(6):678-691.
91. KINDERMANN M, MAACK C, SCHALLER S et al.: Atypical binding of carvedilol to beta adrenoceptors prevents beta blocker rebound phenomenon. Circulation (2003) 108(Suppl. IV):IV-370.
92. SCHAFERS RF, ADLER S, DAUL A et al.: Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. J. Am. Coll. Cardiol. (1994) 23(5):1224-1233.
93. METRA M, CLELAND JG, DI LENARDA A et al.: Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: results from the Carvedilol or Metoprolol European Trial (COMET). J. Am. Coll. Cardiol. (2004) 43 (5 Suppl. A):157A.
94. METRA M, POOLE-WILSON PA, CLELAND JG et al.: Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metoprolol in the patients with heart failure: results from the Carvedilol or Metoprolol European Trial (COMET). J. Am. Coll. Cardiol. (2004) 43(5 Suppl. A): 206A.
95. LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T, BOISSEL JP: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98(12):1184-1191.
96. DOUGHTY RN, RODGERS A, SHARPE N, MACMAHON S: Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur. Heart J. (1997) 18(4):560-565.
97. KRUM H, COATS AJ, FOWLER MB et al.: Safety and tolerability of carvedilol in patients with severe chronic heart failure: results of the COPERNICUS study. Circulation (2001) 104(17 Suppl.):717.
98. DI LENARDA A, POOLE-WILSON PA, CLELAND JG et al., for the COMET INVESTIGATORS: Exchange of beta-blocking therapy in heart failure patients. Experiences from the post-study phase of COMET (The Carvedilol or Metoprolol European Trial). J. Am. Coll. Cardiol. (In Press).
99. REMME WJ, SWEDBERG K, for the Task Force For The Diagnosis And Treatment Of Chronic Heart Failure, European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (2001) 22(17):1527-1560.
100. HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation (2001) 104(24):2996-3007.
101. MERIT-HF STUDY GROUP: Effect of meroprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001-2007.
102. HJALMARSON A, GOLDSTEIN S, FAGERBERG B et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA (2000) 283(10):1295-1302.
103. CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9-13.
104. GOTTLIEB SS, MCCARTER RJ, VOGEL RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. (1998) 339(8):489-497.
105. GHEORGHIADE M, EICHHORN EJ. Practical aspects of using beta-adrenergic blockade in systolic heart failure. Am. J. Med. (2001) 110(Suppl. 7A):68S-73S.
106. GHEORGHIADE M, COLUCCI WS, SWEDBERG K: Beta-blockers in chronic heart failure. Circulation (2003) 107(12):1570-1575.
107. JACOB S, RETT K, WICKLMAYR M, AGRAWAL B, AUGUSTIN HJ, DIETZE GJ: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J. Hypertens. (1996) 14(4):489-494.
108. GIUGLIANO D, ACAMPORA R, MARFELLA R et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. (1997) 126(12):955-959.